![An empirical assessment of research practices across 163 clinical trials of tumor-bearing companion dogs | Scientific Reports An empirical assessment of research practices across 163 clinical trials of tumor-bearing companion dogs | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-019-48425-5/MediaObjects/41598_2019_48425_Fig1_HTML.png)
An empirical assessment of research practices across 163 clinical trials of tumor-bearing companion dogs | Scientific Reports
![A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19 - eClinicalMedicine A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19 - eClinicalMedicine](https://www.thelancet.com/cms/asset/d21a79d0-e889-4023-b8d7-d3a07e2cf38d/gr1.jpg)
A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19 - eClinicalMedicine
![Observed and expected serious adverse event rates in randomised clinical trials for hypertension: an observational study comparing trials that do and do not focus on older people - The Lancet Healthy Longevity Observed and expected serious adverse event rates in randomised clinical trials for hypertension: an observational study comparing trials that do and do not focus on older people - The Lancet Healthy Longevity](https://www.thelancet.com/cms/attachment/bbd58d40-5b11-4ad5-9ff4-fea1865f9c31/gr1.gif)
Observed and expected serious adverse event rates in randomised clinical trials for hypertension: an observational study comparing trials that do and do not focus on older people - The Lancet Healthy Longevity
![Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial - The Lancet Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial - The Lancet](https://www.thelancet.com/cms/asset/04f3d1bc-8493-4bfa-9572-fc2f5606352f/gr1.jpg)
Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial - The Lancet
![Frontiers | Trends of Phase I Clinical Trials of New Drugs in Mainland China Over the Past 10 Years (2011–2020) Frontiers | Trends of Phase I Clinical Trials of New Drugs in Mainland China Over the Past 10 Years (2011–2020)](https://www.frontiersin.org/files/Articles/777698/fmed-08-777698-HTML/image_m/fmed-08-777698-g001.jpg)
Frontiers | Trends of Phase I Clinical Trials of New Drugs in Mainland China Over the Past 10 Years (2011–2020)
![Recruitment of Black Adults into Cardiovascular Disease Trials | Journal of the American Heart Association Recruitment of Black Adults into Cardiovascular Disease Trials | Journal of the American Heart Association](https://www.ahajournals.org/cms/asset/13ef21df-50f4-4ed9-b7c8-0a8329ca19d2/jah36522-fig-0001.png)
Recruitment of Black Adults into Cardiovascular Disease Trials | Journal of the American Heart Association
![Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition | Nature Medicine Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01775-6/MediaObjects/41591_2022_1775_Fig1_HTML.png)
Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition | Nature Medicine
![Prototype of running clinical trials in an untrustworthy environment using blockchain | Nature Communications Prototype of running clinical trials in an untrustworthy environment using blockchain | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-019-08874-y/MediaObjects/41467_2019_8874_Fig1_HTML.png)
Prototype of running clinical trials in an untrustworthy environment using blockchain | Nature Communications
![Investor's Guide To Clinical Trials: Phase Success Rates For Introductory Pipeline Analysis | Seeking Alpha Investor's Guide To Clinical Trials: Phase Success Rates For Introductory Pipeline Analysis | Seeking Alpha](https://static.seekingalpha.com/uploads/2017/3/2/30035385-14884880904879966.jpg)